EXROF Projected Dividend Yield
Exro Technologies Inc ( OTCBB : EXROF )BioDe Ventures is engaged in Omiganan based technologies. Co.'s primary dermatological assets are Omiganan 1% gel (cationic peptide also known as OmigardTM and MX-226) and Omiganan for dermatological diseases (cationic peptide also known as CLS001). This technology may potentially be used for prevention of catheter-related infections and treatment of rosacea and other dermatological diseases. 21 YEAR PERFORMANCE RESULTS |
EXROF Dividend History Detail EXROF Dividend News EXROF Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |